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In cystic fibrosis (CF), transcript analysis and quantification are important for diagnosis, prognosis and also as surrogate markers for some
therapies including gene therapy. Classical RNA-based methods require significant expression levels in target samples for appropriate
analysis, thus PCR-based methods are evolving towards reliable quantification. Various protocols for the quantitative analysis of CFTR
transcripts (including those resulting from splicing variants) are described and discussed here.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Transcripts; RT-PCR; Quantitative PCR; Real-time PCR; Splicing; Alternative splicing1. Introduction
In cystic fibrosis (CF), there are three aspects of clinical
utility of transcript analysis and quantification as tools for
disease diagnosis and monitoring, namely: (1) the absolute
quantification of CFTR transcripts in different tissues; (2)
assessment of the qualitative and quantitative impact of
certain gene variants on splicing, by measurement of the
relative levels of aberrantly spliced isoforms; (3) definition
of novel molecular parameters as prognostic markers for1569-1993/$ - see front matter D 2004 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2004.05.047
Abbreviations: CERES, Composite Exonic Regulatory Element of
Splicing; ddNTPs, dideoxynucleotides; NBD, nucleotide-binding domain;
OAT, ornithine amino transferase; PCR, polymerase chain reaction; RT,
reverse transcriptase; SAB, sum above background.
* Corresponding author. Department of Chemistry and Biochemistry,
University of Lisboa, Lisboa, Portugal. Tel.: +351-21-750-08-61; fax:
+351-21-750-00-88.
E-mail address: mdamaral@fc.ul.pt (M.D. Amaral).disease evolution (RNA expression profiling that might
provide novel diagnostic or prognostic tools for assessment
of CF patients is dealt with in a separate article of the
present supplement [1]).
The first of these applications is important for: (i)
identification of relevant target tissues/cells for therapy;
(ii) determination of the residual levels of normal, full-
length CFTR transcripts that may have prognostic signifi-
cance; (iii) as surrogate markers to evaluate response to gene
therapy, or to pharmacological agents aimed at increasing
the levels of CFTR gene expression (e.g., phenyl butyrate).
The classic methods of Northern or Southern blot allow
reliable quantification of unamplified DNA or RNA, but
require the target molecule to be present at a high-copy
number in samples. In contrast, polymerase chain reaction
(PCR)-based techniques allow quantification by specific
amplification of nucleic acid sequences starting with a very
low copy number and/or limited amounts of sample. Re-
verse transcriptase (RT)-PCR therefore represents a sensi-ed by Elsevier B.V. All rights reserved.
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RT-PCR has tremendous potential, although a comprehensive
knowledge of its technical aspects is required. Successful
quantitative RT-PCR involves correction for experimental
variations in individual RT reactions and often correction for
different PCR efficiencies using external standards. These
parameters are described below in detail.
Recent technological advances allow detection of the
increment per cycle of a specific PCR product in ‘‘real-time
mode’’. This technology has set the stage for the reliable
quantification of very small amounts of nucleic acids in
extremely small samples, possibly even single cells. This
technique has already been successfully applied to the
quantification of both CFTR DNA and RNA (including
splice variants) from several sources, and is also discussed
here.
Besides practical considerations of experimental design,
we also address here absolute quantification by RT-PCR,
choice of RNA standards (internal vs. external) and a
number of quantification strategies, all in a CF context.
All protocols referred to here are described elsewhere in
further detail [2].
In a scenario of application of some of these techniques
to the diagnosis (and possibly prognosis and/or therapy
assessment) of CF, we envisage that new guidelines, as
well as extensive quality control and standardization pro-
grams, must be introduced.2. Choice of primers
Successful and optimal analysis of transcripts by RT-
PCR requires a careful design of oligonucleotide primers.
This can be achieved simply by inspection of the sequence
to be amplified, or by using software packages either freely
available online [3–5] or included with certain real-time
thermocycler machines (e.g., PrimerExpressk, Applied
Biosystems, Foster City, CA, USA). To quantitatively assess
splicing variants, primers can be selected to produce reac-
tion products, which serve as their own internal competitors
(by spanning the alternative splice variants). All methods
discussed here imply the previous extraction of RNA from
samples, as described elsewhere [6].1 Almost all F508del chromosomes detected in CF patients and carriers
all over the world are associated the same extended haplotype and TG10T9
[28].3. Methods for absolute or relative quantification of
CFTR transcripts
3.1. RT-PCR quantification of CFTR mRNA in human
samples with one F508del allele
This RT-PCR protocol allows the relative quantification
of CFTR transcripts from CF carriers or patients possessing
the F508del mutation in one allele. The strategy also allows
transcripts with and without skipping of exon 9 [2,7] to be
distinguished, and thus quantified. Additionally, by assum-ing that levels of transcripts from the F508del-CFTR allele
are constant among different individuals, this method also
allows estimation of the absolute level of non-F508del
transcripts present.
Briefly, a PCR product in the region of exons 8–10 is
amplified. Aliquots are collected at different cycle numbers
(e.g., n, n + 1, n + 2, n+ 3) to verify that the reaction is still
in the exponential phase, and the products separated and
detected in an automatic sequencer. Unequal amplification
efficiencies of transcripts with and without exon 9 are
corrected for by use of control plasmids. Percentage of each
CFTR mRNA species is estimated relative to total CFTR
present, by integration of the corresponding PCR product
peak areas using GeneScank software (Applied Biosys-
tems). The absolute amount of transcripts from the non-
F508del CFTR allele is then calculated, using raw data
obtained from integration of peak areas from separate
analysis of samples from each individual (CF carrier or
patient). Here, F508del transcripts are considered as internal
standards, i.e., assumed as non-variant among individuals.1
3.2. Relative quantification of CFTR mRNA by RT-PCR
using b-actin as an internal standard
This protocol allows the relative quantification of CFTR
transcripts (target) in mRNA samples, by comparison with
the mRNA abundance of h-actin (control), a housekeeping
gene which is assumed to be expressed at roughly equal
levels in different cell types and under different conditions.
The protocol [2] differs from the one above in that it does
not require presence of the F508del allele, and is thus a
more general method for detection of differences in CFTR
mRNA expression levels among different samples. Briefly,
a duplex RT-PCR is performed using FAM-labelled primers
to amplify CFTR and h-actin cDNAs from the same RNA
samples, originating products of similar (and relatively
small) size to minimize differences in amplification effi-
ciencies. As above, aliquots are taken after increasing
numbers of PCR cycles, the products are run on an auto-
matic sequencer, and PCR product abundance estimated by
integrating the corresponding peak areas using GeneScank
software. Provided both products are still in the logarithmic
phase of amplification (see above and also Ref. [6]), which
can be shown by plotting peak areas against number of
cycles for both products, CFTR mRNA abundance is then
calculated as a percentage of h-actin expression. For very
low abundance mRNAs (e.g., CFTR, in most cell types) it is
also possible to mix normal and competitive non-extendable
h-actin primers, synthesized with dideoxynucleotides
(ddNTPs) at their 3Vends, to artificially ‘‘tune’’ the ampli-
fication reactions of both transcripts (target and control) to
the logarithmic phase and thereby allow comparison.
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replication (n = 3 or more independent experiments) fol-
lowed by statistical analysis. It is important to remember
that this is a relative method of quantification, and resulting
values can only be compared with others obtained in the
same reaction or under identical experimental conditions,
particularly if competitive actin primers are used.
3.3. Quantitative sheep, human and mouse CFTR transcript
analysis by real-time PCR (TaqMank)
The protocol that we optimized for the quantitative anal-
ysis of sheepCFTR transcripts [2] used a probe and primer set
designed by ABI PrimerExpressk 1.0 software and is spe-
cific for RT-PCR as the probe spans the boundary of exons 6a
and 6b of ovine CFTR. This area of the transcript has been
shown by our laboratory not to exhibit any significant
alternative splicing. The probe can be labelled with FAM
and TAMRA. More recently probe and primer sets have been
optimized for the detection of human CFTR with a probe
spanning the boundaries of exons 5 and 6a and mouse CFTR
with a probe spanning the boundaries of exons 16 and 17a.
TaqMank equipment provides instructions on how to
determine ideal probe and primer reaction concentrations.
This may have to be determined each time a new probe is
ordered, even if the sequence is the same. A small amount of
detectable target RNA should be used in the optimization
procedure.
To obtain meaningful values, the same experimental
sample should be assayed with an internal control. Due to
the lack of availability of a suitable, well-characterized,
sheep-specific internal control, we used a ribosomal RNA
assay.2 This assay works for species as diverse as Saccha-
romyces cerevisiae and human. However, it has the major
disadvantage that 18S rRNA is expressed at an extremely
high level compared to CFTR, and, as a result, extensive
dilution of the sample is required to generate reproducible
results. In general, it is best to use an internal control with
equivalent expression levels to the gene under investigation.
It is sometimes possible to assay control and target gene
expression in the same sample within the same tube if dif-
ferent labels are used as on each probe and the probe/primer
sets function efficiently in the same reaction conditions.
3.4. RT-PCR based quantification of CFTR YAC copy
number
This RT-PCR based quantitative method is designed for
detection of YAC transgene expression in both human cells
and transgenic mice, normalized per YAC copy number.2 Closer inspection of the sequences of primers included in the 18S
rRNA kit (Applied Biosystems) revealed that the 3V primer actually
overlapped with the probe by a single thymidine residue. All 18SrRNA
reactions performed by our laboratory (Institution 3) used these sequences
despite this error and results were reproducible.RNA samples prepared from cell lines or transgenic mouse
tissues is first reverse transcribed with oligo-dT primer, and
an aliquot of the cDNA thus produced is used in the specific
PCR reaction with a radio-labelled primer [2].
3.4.1. Analysis of transgenic mouse tissues
For the analysis of transgenic mouse tissues, RT-PCR
products are digested with NruI (digests the human YAC
product) and HindIII (digests the mouse product) and then
separated by agarose gel electrophoresis. The latter is dried
prior to exposure to a phosphorimager screen for radioac-
tivity counting. After recording the sum above background
(SAB) counts from the 566 bp mouse digestion product
fragment (mouse-SAB) and the 390 bp human digestion
product (human-SAB), the mouse-SAB is divided by 326
and the human-SAB by 221 for normalization, accounting
for the AT content of each fragment. Each normalized SAB
is then corrected to a copy number of 2 (e.g., if the YAC
copy number has been estimated at 3, divide the normalized
SAB by 2/3) for comparison.
3.4.2. Analysis of human cell lines
For the analysis of human cell lines, a very similar
protocol is used, except that digestion of RT-PCR products
is carried out with restriction enzymes ClaI (specific for the
human YAC product) and BclI (specific for the endogenous
gene). These yield radioactive products of 590 bp (endog-
enous gene digestion product) and 590 bp (YAC digestion
product). Following exposure to a phosphorimager screen
and recording of SAB from these products, SAB values
normalized for their respective AT content are also corrected
to a copy number of 2, as above, for comparison.
3.5. Methods for differentiation/quantification of normal
and mutant CFTR mRNAs. Example: E822X
Nasal epithelial cells are collected as described [6] from
individuals with mutation E822X (G>T at 2596), non-CF
controls and heterozygotes for the polymorphism R668C,
and mRNA extracted. First strand cDNA is synthesized
using random hexanucleotide primers. RT-PCR is per-
formed using Hot Star polymerase (Qiagen, Hilden, Ger-
many) as described [2,9]. An aliquot of the final products is
loaded on an automatic DNA sequencer. Each analysis is
repeated three times to ensure accurate quantification. Rel-
ative amounts of mutant and normal cDNA products are
sized and quantified using the Fragmentor analysis software,
and are expressed as percentage of total cDNA.
3.5.1. E822X
RNA samples with E822X are reverse-transcribed with
an initial primer set spanning exons 13 to 14a. The forward
primer was designed to contain a 3Vmismatch (G>A at
25943) which in combination with the normal sequence at3 Numbering system according to Zielenski et al. [29].
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site for Hph1, whereas the mutant transcript remains intact.
The reverse primer is end labeled with the fluorescent
moiety Texas-Red.
3.5.2. Quantification of mutant/normal cDNA
Amodification of the RT-PCR protocol is used to quantify
the levels of mutant/normal (822X/E822) mRNA by one-step
extension of the fluorescent primer, using an aliquot of
previously amplified CFTR cDNA as template. The product
is Hph1 digested and analyzed on an automatic sequencer as
above. The one-step primer extension avoids formation of
normal/mutant heteroduplexes that remain uncleaved by the
restriction enzyme, leading to false ratios. The quantification
is validated by including homozygous mutant and normal
controls.4. Detection and quantification of CFTR splicing
variants
Several CFTR splicing mutations have been shown to
generate both correctly and aberrantly spliced transcripts.
Some quantification strategies for splice variants are dis-
cussed here.
4.1. One-step RT-PCR method to determine low levels of
aberrantly spliced CFTR mRNAs
4.1.1. General strategy of the assay
This protocol describes a sensitive, accurate and rapid
real-time one-step RT-PCR method for measuring low
abundance CFTR splice variants. The use of well-validated
boundary-spanning primers has been shown to be the most
accurate method of real-time PCR for quantification of
splice variants, which differ greatly in abundance [10,11].
4.1.2. Quantitative one-step RT-PCR
Quantification of CFTR mRNA is difficult because of its
low abundance with only 1–2 copies per cell in the
respiratory tract [12] and cell yields of nasal brushings from
children are low. Consequently, to reach a good degree of
sensitivity and specificity, three methods were combined.
First, CFTR transcripts with and without exon 9 (ex9+;
ex9) are reverse transcribed with the same reverse primer
in exon 10, as the selection of gene specific primers for low
abundance transcripts is recommended [13]. The first five
bases of the forward primer for both transcripts are com-
plementary to exon 10. The residual 16 bases of the forward
primer are identical to the 3V end of exon 9 for CFTR 9
transcripts and to the 3V end of exon 8 for CFTR ex9
transcripts. These primers not only discriminate between
ex9+ and ex9 transcripts, but also prevent amplification of
contaminating genomic DNA. Secondly, for the real-time
PCR a hot-start approach was used for reduction of non-
specific products. Thirdly, the rapid cycle DNA amplifica-tion is a LightCycler specific PCR technique with improved
product specificity and fast cycle times [14]. With this
technique, an allele-specific assay can even discriminate
between a 3-bp or a 1-bp mismatch at the 3V end of the
corresponding primers [15].
4.1.3. Diagnostic accuracy and reproducibility
Identical amplification efficiency of the two splice var-
iants is essential for reliable and reproducible relative and
absolute quantitative real-time RT-PCR. All calibration
curves for CFTR ex9+ and ex9 standards (each diluted
from 107 to 103 copies of single-stranded DNA per reaction
mixture) showed linearity over the entire range with corre-
lation coefficients >0.99, indicating a precise log-linear
relationship. The intrarun variability, calculated from dupli-
cates of the two targets, showed a maximal average S.D. of
3.8%. For interrun variability the threshold cycle was
determined in duplicates for both splice variants for each
sample in four independent analytical runs, and mean
threshold cycle was used to determine a maximal interassay
S.D. of 6.0%.
4.2. Semi-quantitative RT-PCR for alternatively spliced
exons: 3849+10 Kb C->T and IVS8-polyT
Quantification of CFTR splice variants is performed by
fluorescent RT-PCR analysis. The PCR primers flank the
alternatively spliced exon, and, therefore, generate two
products in each PCR reaction, one including and one
lacking the alternatively spliced exon. One of the primers
is fluorescently labeled, thus all PCR products are fluores-
cent and can be quantified in an automated sequencer. The
analysis is performed using GeneScank software (see
above). The level of any given transcript (aberrantly or
correctly spliced) is determined as the signal peak area of
the corresponding PCR product divided by the sum of the
signal peak areas of both aberrantly and correctly spliced
PCR products. The PCR is performed under semi-quantita-
tive conditions as determined by serial tertiary dilutions of
the cDNA, and is defined for each set of primers. The
quantitative range lies within the linear range, so assays
should be designed accordingly.
4.2.1. The 3849+10 Kb C->T mutation
The primers used are as described elsewhere [2] and bind
to sites in exons 18 and 20. The reverse primer is fluo-
rescently labelled with 6-FAM. The PCR products of the
correctly and aberrantly spliced transcripts are 304 and 388
bp, respectively. The aberrantly spliced transcript includes a
cryptic ‘exon’ of 84 bp (between exons 19 and 20), which
bears a stop codon [16]. Therefore, the total amount of the
transcripts has to be calculated [17].
4.2.2. The IVS8-polyT alleles
The primers used bind to exons 8 and 10, respectively.
The reverse primer is fluorescently labelled with 6-FAM.
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spliced transcripts are 513 and 330 bp, respectively. The
primer sequences and PCR protocol are available at the
European Working Group on CFTR Expression website [2].5. Minigene functional analysis of CFTR splicing
transcripts
5.1. General strategy of the hybrid minigene transient
transfection assay for the identification and analysis of
splicing defects
Intronic and exonic sequences contain several splicing
regulatory elements important for correct processing of
mRNA. Human mutations interfering with these regulatory
elements may cause splicing defects. The most common
splicing mutations affect canonical elements such as the
conserved 3V(AG) or 5V(GT) splice sites, or the branch site.
However, pre-mRNA splicing alterations that modify non-
canonical regulatory elements are more difficult to detect by
sequence inspection alone. As RNA samples from patients
are not always available, hybrid minigenes represent an
important tool for the study and characterization of the
effect of human genetic variations/mutations on the pattern
or efficiency of pre-mRNA splicing. Any region of interest
suspected to cause a splicing defect (e.g., a specific exonFig. 1. Mutations in Composite Regulatory Elements of Splicing (CERES) in CFTR
available point substitutions in the CF database [23]. Some missense and silen
substitutions never analyzed for splicing efficiency are shown in italics. (b) Sch
alternative splicing of CFTR exon 12. These minigenes contains normal exon 12 (W
globin, fibronectin, and CFTR exons are shown as black, shaded and white boxes, r
SV40 enhancer (small arrow at the 3Vend). For details see Ref. [2]. (c) The effect of
inclusion. The wt exon 12 minigene shows about 80% of exon inclusion. D565
percentage of exon 12 inclusion. Data are from Ref [22].along with flanking intronic sequences) is introduced into a
minigene and transfected into cell lines. The minigene
described here is transcribed by polymerase II into pre-
mRNA and accurately spliced in the cell. This approach,
initially described for the study of basic mechanisms of
alternative splicing [18], has been recently validated for the
study of the effect of mutations and/or polymorphic variants
on the processing of the nascent RNA in several genes,
including CFTR [8,19–22]. The mRNA is analyzed by RT-
PCR with primers that amplify processed transcripts derived
from the minigene. Two different examples are described
here, and detailed protocols can be found at the European
Working Group on CFTR Expression website [2].
5.2. Nucleotide substitutions in exonic regulatory elements:
missense and silent mutations in Composite Exonic Regula-
tory Elements of splicing in CFTR exon 12
Exonic sequence variations overlap with coding sequen-
ces and thus are frequently considered only for their effect
on the protein, e.g., when missense mutations modify amino
acid composition. Synonymous or silent variations are
largely ignored, but may have unexpected and unpredictable
effects on splicing, with variable amounts of exon skipping.
Exonic substitutions may affect novel regulatory elements
termed Composite Exonic Regulatory Elements of Splicing
(CERES) [22]. These are short exonic RNA sequences (5–exon 12. (a) Nucleotide sequence of the CFTR exon 12 showing the list of
t variations (highlighted) are located in the CERES elements. Nucleotide
ematic representation of the three hybrid minigenes used for analysis of
Tex12) or the four natural mutations occurring in CERES elements. The a-
espectively. Arrows indicate RT-PCR primers. Transcription is driven by the
natural CFTR exon 12 mutants. The graph shows the percentage of exon 12
G, G576A and Y577Y induce exon skipping, while Y577F increases the
Fig. 2. CFTR–OAT hybrid minigene.
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for splicing regulation where different substitutions at near-
by (or the same) positions can have opposing effects on
splicing efficiency [22]. CFTR exon 12 contains several
sequence variations (see CF mutations database [23]) (Fig.
1a) associated with different CF phenotypes, including
classical and non-classical CF. Some are considered benign
polymorphic variants and for several, a clear disease-caus-
ative role is missing. In particular, two missense mutations,
D565G and G576A (previously considered a neutral poly-
morphism), showed no clear association with loss of protein
function or disease phenotype. The effect of these variations
on the splicing process was evaluated using a suitable
hybrid minigene (Fig. 1b). Skipping of exon 12 removes a
highly conserved region encoding part of the first nucleo-
tide-binding domain (NBD1) of CFTR, rendering the pro-
tein non-functional. Using the hybrid minigene, these
natural mutations were found located in CERES elements.
D565G and G576A induce variable levels of exon 12
skipping, thus reducing levels of normal transcripts. Anoth-
er missense mutation, Y577F, reported in a patient with
severe CF [23], increased the amount of transcript with this
exon in comparison to non-CF controls (Fig. 1c), suggesting
that this amino acid substitution was directly responsible for
the severe phenotype. Interestingly, the synonymous Y577Y
substitution caused exon skipping indicating that ‘‘benign’’
variants have to be assessed for splicing efficiency. This
study was reinforced by characterization of the splicing
pattern in patient samples where the patterns with the
minigene and in cells harbouring the natural mutation were
in concordance [22]. CERES-like elements have also been
observed in CFTR exon 9 [21] and have been suggested to
occur in exons 10 and 11 [24].
5.3. Minigene assay for the evaluation of CFTR exon 9
splicing efficiency
CFTR exon 9 is frequently and extensively skipped, and
is caused primarily by an abbreviated version of the poly-
pyrimidine tract in the splice acceptor of exon 9 called the
5T allele. High proportions of transcripts lacking exon 9
combined in trans with a severe CFTR mutation can lead to
atypical CF, most commonly congenital bilateral absence of
the vas deferens (CBAVD). Minigenes provide a controlled
system with which to isolate cis and trans factors that affect
the splicing of this and other exons [16,19,20,25,26]. To
study factors affecting CFTR exon 9 splicing, we designed a
transfectable minigene that incorporated exon 9 and its
flanking intronic sequence. To retain the appropriate cis
elements and approximate the in vivo splicing context for
exon 9, the 3Vand 5Vends of exons 8 and 10, respectively,
were also included. We have used this minigene to assess
the contribution of splice sites, the polypyrimidine tract
(Tn), and the adjacent TG dinucleotide repeat (TG)m to
exon 9 skipping [26,27]. CFTR exon 9 minigenes have been
also used to identify specific RNA trans-acting factorsbinding to the (TG)m repeat [30,31]. An example of a
CFTR exon 9 minigene is shown in Fig. 2.
5.3.1. Minigene construction and assay
The minigene was created by amplifying genomic DNA
from a control sample. Exon 9, portions of exons 8 and 10,
and flanking intronic sequences are included (Fig. 2).
Genomic DNA was amplified by PCR, introducing unique
restriction sites to enable subsequent ligation of the mini-
gene components. These were introduced in-frame to an
ornithine amino transferase (OAT) cDNA and inserted into
the expression plasmid pBK-RSV (Clontech, Palo Alto, CA,
USA). The minigene construct can be introduced into any
transfectable cell line, e.g., HEK293, and allowed to express
for 24 h, after which total RNA is harvested, cDNA is
synthesized, and RT-PCR performed. The 5V primer is
specific for the 5VOAT sequence, and is 6-FAM-labelled.
The unlabelled 3Vprimer is specific for CFTR exon 10. PCR
products are analysed in an automatic sequencer. ABI’s
GeneScank software automatically calculates peak area
measurements, which are used to estimate the total amount
of product derived from each splice variant. A detailed
description of the protocol used in the analysis of hybrid
minigenes can be found online [2].Acknowledgements
The preparation of this review was supported by the EU-
European Thematic Network on Cystic Fibrosis and Related
Diseases (EU-QLK3-CT-1999-00241) and grants from the
Italian Cystic Fibrosis Research Foundation, the Cystic
Fibrosis Trust (UK), Vaincre La Mucoviscidose (France),
the Portuguese Foundation for Science and Technology
(POCTI/1999/MGI/35737; POCTI/MGI/47382/2002) and
the EU (‘‘CF-Chip’’ EU-QLK3-CT-2001-01982).References
[1] Galvin P, Clarke LA, Harvey S, Amaral MD. Microarray analysis in
Cystic Fibrosis. J Cystic Fibros 2004;3:S1 [in press].
[2] The Online Virtual Repository of Methods and Reagents for CFTR
Expression and Functional Studies (Section A): http://central.igc.
gulbenkian.pt/cftr/vr/transcripts.html.
[3] Berkeley Drosophila Genome Project Splice Site Prediction by Neural
Network. http://www.fruitfly.org/seq_tools/splice.html/.
M.D. Amaral et al. / Journal of Cystic Fibrosis 3 (2004) 17–23 23[4] Saccharomyces Genome Database Web Primer. http://genome-www2.
stanford.edu/cgi-bin/SGD/web-primer/.
[5] Primo Pro 3.4. http://www.changbioscience.com/primo/primo.html.
[6] Ramalho AS, Beck S, Farinha CM, Clarke LA, Heda GD, Steiner B,
et al. Methods for RNA extraction, cDNA preparation and analysis
of CFTR transcripts. J Cystic Fibros 2004;3:11–5. doi:10.1016/
j.jcf.2004.05.004.
[7] Ramalho AS, Beck S, Meyer M, Penque D, Cutting GR, Amaral MD.
Five percent of normal cystic fibrosis transmembrane conductance
regulator mRNA ameliorates the severity of pulmonary disease in
cystic fibrosis. Am J Respir Cell Mol Biol 2002;27(5):619–27.
[8] Pagani F, Buratti E, Stuani C, Bendix R, Dork T, Baralle FE. A new
type of mutation causes a splicing defect in ATM. Nat Genet
2002;30(4):426–9.
[9] Tzetis M, Efthymiadou A, Doudounakis S, Kanavakis E. Qualitative
and quantitative analysis of mRNA associated with four putative
splicing mutations (621 + 3A–>G, 2751 + 2T–>A, 296 + 1G–>C,
1717-9T–>C-D565G) and one nonsense mutation (E822X) in the
CFTR gene. Hum Genet 2001;109(6):592–601.
[10] Vandenbroucke II, Vandesompele J, Paepe AD, Messiaen L. Quanti-
fication of splice variants using real-time PCR. Nucleic Acids Res
2001;29(13):E68.
[11] Wong YW, Sia GM, Too HP. Quantification of mouse glial cell-line
derived neurotrophic factor family receptor alpha 2 alternatively
spliced isoforms by real time detection PCR using SYBR Green I.
Neurosci Lett 2002;320(3):141–5.
[12] Bremer S, Hoof T, Wilke M, Busche R, Scholte B, Riordan JR, et al.
Quantitative expression patterns of multidrug-resistance P-glycopro-
tein (MDR1) and differentially spliced cystic-fibrosis transmembrane-
conductance regulator mRNA transcripts in human epithelia. Eur J
Biochem 1992;206(1):137–49.
[13] Lekanne Deprez RH, Fijnvandraat AC, Ruijter JM, Moorman AF.
Sensitivity and accuracy of quantitative real-time polymerase chain
reaction using SYBR green I depends on cDNA synthesis conditions.
Anal Biochem 2002;307(1):63–9.
[14] Wittwer CT, Herrmann MG, Gundry CN, Elenitoba-Johnson KS.
Real-time multiplex PCR assays. Methods 2001;25(4):430–42.
[15] Wittwer CT, Marshall BC, Reed GH, Cherry JL. Rapid cycle allele-
specific amplification: studies with the cystic fibrosis delta F508 lo-
cus. Clin Chem 1993;39(5):804–9.
[16] Nissim-Rafinia M, Chiba-Falek O, Sharon G, Boss A, Kerem B.
Cellular and viral splicing factors can modify the splicing pattern of
CFTR transcripts carrying splicing mutations. Hum Mol Genet
2000;9(12):1771–8.
[17] Chiba-Falek O, Kerem E, Shoshani T, Aviram M, Augarten A, Bentur
L, et al. The molecular basis of disease variability among cystic
fibrosis patients carrying the 3849 + 10 kb C–>T mutation. Genomics
1998;53(3):276–83.
[18] Vibe-Pedersen K, Kornblihtt AR, Baralle FE. Expression of a humanalpha-globin/fibronectin gene hybrid generates two mRNAs by alter-
native splicing. EMBO J 1984;3(11):2511–6.
[19] Niksic M, Romano M, Buratti E, Pagani F, Baralle FE. Functional
analysis of cis-acting elements regulating the alternative splicing of
human CFTR exon 9. Hum Mol Genet 1999;8(13):2339–49.
[20] Pagani F, Buratti E, Stuani C, Romano M, Zuccato E, Niksic M, et al.
Splicing factors induce cystic fibrosis transmembrane regulator exon
9 skipping through a nonevolutionary conserved intronic element.
J Biol Chem 2000;275(28):21041–7.
[21] Pagani F, Buratti E, Stuani C, Baralle FE. Missense, nonsense, and
neutral mutations define juxtaposed regulatory elements of splicing in
cystic fibrosis transmembrane regulator exon 9. J Biol Chem 2003;
278(29):26580–8.
[22] Pagani F, Stuani C, Tzetis M, Kanavakis E, Efthymiadou A, Doudou-
nakis S, et al. New type of disease causing mutations: the example of
the composite exonic regulatory elements of splicing in CFTR exon
12. Hum Mol Genet 2003;12(10):1111–20.
[23] The Cystic Fibrosis Mutation Database. http://www.genet.sickkids.
on.ca/cftr/.
[24] Ramalho AS, Beck S, Penque D, Gonska T, Seydewitz HH, Mall M,
et al. Transcript analysis of the cystic fibrosis splicing mutation 1525-
1G>A shows use of multiple alternative splicing sites and suggests a
putative role of exonic splicing enhancers. J Med Genet 2003;40(7):
e88.
[25] Dietz HC, Kendzior Jr RJ. Maintenance of an open reading frame as
an additional level of scrutiny during splice site selection. Nat Genet
1994;8(2):183–8.
[26] Hefferon TW, Broackes-Carter FC, Harris A, Cutting GR. Atypical 5V
splice sites cause CFTR exon 9 to be vulnerable to skipping. Am J
Hum Genet 2002;71(2):294–303.
[27] Hefferon TW, Groman JD, Yurk CD, Cutting GR. A variable dinu-
cleotide repeat in the CFTR gene contributes to phenotype diversity
by forming RNA secondary structures that alter splicing, Proc Natl
Acad Sci U S A 2004;101(19):3504–9.
[28] Do¨rk T, Neumann T, Wulbrand U, Wulf B, Kalin N, Maass G, et al.
Intra- and extragenic marker haplotypes of CFTR mutations in cystic
fibrosis families. Hum Genet 1992;88(4):417–25.
[29] Zielenski J, Rozmahel R, Bozon D, Kerem B, Grzelczak Z, Riordan
JR, et al. Genomi DNA sequence of the Cystic Fibrosis Transmem-
brane Conductance Regulator (CFTR) Gene. Genomics 1991;10(1):
214–28.
[30] Buratti E, Do¨rk T, Zuccato E, Pagani F, Romano M, Baralle FE.
Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo
CFTR exon 9 skipping. EMBO J 2001;20(7):1774–84.
[31] Buratti E, Baralle FE. Characterization and functional implications
of the RNA binding properties of nuclear factor TDP-43, a novel
splicing regulator of CFTR exon 9. J Biol Chem 2001;276(39):
36337–43.
